Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quinvaxem in Uniject vs Vials in Healthy Infants
NCT01917357Phase 3Completed
- Sponsor
- Crucell
- Start
- Sep 2013
- Primary completion
- Apr 2014
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Quinvaxem in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by Crucell. Started Sep 2013; status: completed.
02
Drugs
Quinvaxem
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01917357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01917357.